首页> Haematologica> The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents.

The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents.

导出 OA

翻译打印收藏纠错

第一作者： Chiara,Tarantelli

第一单位： Università della Svizzera Italiana, Institute of Oncology Research, Bellinzona, Switzerland.

作者： Chiara,Tarantelli ^[1] ; Lu,Zhang ^[2] ; Elisabetta,Curti ^[1] ; Eugenio,Gaudio ^[1] ; Filippo,Spriano ^[1] ; Valdemar,Priebe ^[1] ; Luciano,Cascione ^[1] ; Alberto J,Arribas ^[1] ; Emanuele,Zucca ^[3] ; Davide,Rossi ^[4] ; Anastasios,Stathis ^[3] ; Francesco,Bertoni ^[5]

作者单位： Università della Svizzera Italiana, Institute of Oncology Research, Bellinzona, Switzerland. ^[1] Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.;Institute of Hematology, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. ^[2] Oncology Institute of Southern Switzerland, Bellinzona, Switzerland. ^[3] Università della Svizzera Italiana, Institute of Oncology Research, Bellinzona, Switzerland.;Oncology Institute of Southern Switzerland, Bellinzona, Switzerland. ^[4] Università della Svizzera Italiana, Institute of Oncology Research, Bellinzona, Switzerland frbertoni@mac.com. ^[5]